» Articles » PMID: 30996573

Clinical Features and Outcomes of Diffuse Large B-cell Lymphoma Based on Nodal or Extranodal Primary Sites of Origin: Analysis of 1,085 WHO Classified Cases in a Single Institution in China

Overview
Specialty Oncology
Date 2019 Apr 19
PMID 30996573
Citations 43
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To explore the clinicobiologic features and outcomes of diffuse large B-cell lymphoma (DLBCL) patients in China according to the primary site.

Methods: A total of 1,085 patients diagnosed with DLBCL in National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College during a 6-year period were enrolled. Their clinical characteristics and outcomes were analyzed according to the primary site.

Results: In the 1,085 patients, 679 (62.6%) cases were nodal DLBCL (N-DLBCL) and 406 cases (37.4%) were extranodal DLBCL (EN-DLBCL). The most common sites of N-DLBCL were lymphonodus (64.8%), Waldeyer's ring (19.7%), mediastinum (12.8%) and spleen (2.7%), while in EN-DLBCL, stomach (22.4%), intestine (16.0%), nose and sinuses (8.9%), testis (8.4%), skin (7.9%), thyroid (6.9%), central nervous system (CNS) (6.4%), breast (5.7%), bone (3.4%), and salivary gland (2.7%) were most common. N-DLBCL patients tend to present B symptoms, bulky disease, and elevated LDH more often, while age >60 years, extranodal sites >1, Ann Arbor stage I or II, bone marrow involvement, and Ki-67 index >90% were usually seen in EN-DLBCL. The 5-year overall survival (OS) rate and progression-free survival (PFS) rate for all patients were 62.5% and 54.2%. The 5-year OS rate for patients with N-DLBCL and EN-DLBCL were 65.5% and 56.9% (P=0.008), and the 5-year PFS were 57.0% and 49.0% (P=0.020). Waldeyer's ring originated DLBCL possessed the highest 5-year OS rate (83.6%) and PFS rate (76.9%) in N-DLBCL. The top five EN-DLBCL subtypes with favorable prognosis were stomach, breast, nose and sinuses, lung, salivary gland, with 5-year OS rate: 70.3%, 69.6%, 69.4%, 66.7% and 63.6%, respectively. While CNS, testis, oral cavity and kidney originated EN-DLBCL faced miserable prognosis, with 5-year OS rate of 26.9%, 38.2%, and 42.9%.

Conclusions: In our study, primary sites were associated with clinical characteristics and outcomes. Compared with EN-DLBCL, N-DLBCL had better prognosis.

Citing Articles

Tonsillar Diffuse Large B-Cell Lymphoma of Non-Germinal Center Type With Cluster of Differentiation 5 Positive in a Pediatric Girl.

Alharbi I, Salawati F, Alnajjar S, Alabbasi A J Med Cases. 2024; 15(11):324-329.

PMID: 39421222 PMC: 11483147. DOI: 10.14740/jmc4288.


Clinical and Biomarker Characteristic of Lymphoma Patients in Hasan Sadikin Lymphoma Registry.

Oehadian A, Kartikasari A, Mersiana L, Gunadi S, Fungani G, Vidyaniati P J Blood Med. 2024; 15:341-349.

PMID: 39132284 PMC: 11314504. DOI: 10.2147/JBM.S472791.


Establishment of Prognosis Nomogram for Primary Splenic Diffuse Large B Cell Lymphoma: A Study Based on SEER Database.

Yonghao O, Yongyang W, Siqing Y, Chengchao F, Lihua C, Xin L Indian J Hematol Blood Transfus. 2024; 40(2):220-230.

PMID: 38708154 PMC: 11065835. DOI: 10.1007/s12288-023-01706-6.


Diffuse large B-cell lymphoma with contemporary involvement of central and peripheral nervous system: A case report and literature review.

Tang C, Jiang P, Tang J, Liao J, Zeng Q Heliyon. 2024; 10(7):e28552.

PMID: 38560176 PMC: 10981111. DOI: 10.1016/j.heliyon.2024.e28552.


Long-term outcomes with HLX01 (HanliKang), a rituximab biosimilar, in previously untreated patients with diffuse large B-cell lymphoma: 5-year follow-up results of the phase 3 HLX01-NHL03 study.

Qin Y, Song Y, Wang D, Bai O, Feng J, Sun X BMC Cancer. 2024; 24(1):124.

PMID: 38267866 PMC: 10809427. DOI: 10.1186/s12885-024-11876-9.


References
1.
Zucca E, Roggero E, Bertoni F, Conconi A, Cavalli F . Primary extranodal non-Hodgkin's lymphomas. Part 2: Head and neck, central nervous system and other less common sites. Ann Oncol. 1999; 10(9):1023-33. DOI: 10.1023/a:1008313229892. View

2.
Rosenwald A, Wright G, Chan W, Connors J, Campo E, Fisher R . The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002; 346(25):1937-47. DOI: 10.1056/NEJMoa012914. View

3.
Krol A, le Cessie S, Snijder S, Kluin-Nelemans J, Kluin P, Noordijk E . Primary extranodal non-Hodgkin's lymphoma (NHL): the impact of alternative definitions tested in the Comprehensive Cancer Centre West population-based NHL registry. Ann Oncol. 2002; 14(1):131-9. DOI: 10.1093/annonc/mdg004. View

4.
Hans C, Weisenburger D, Greiner T, Gascoyne R, Delabie J, Ott G . Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2003; 103(1):275-82. DOI: 10.1182/blood-2003-05-1545. View

5.
Abrey L, Batchelor T, Ferreri A, Gospodarowicz M, Pulczynski E, Zucca E . Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol. 2005; 23(22):5034-43. DOI: 10.1200/JCO.2005.13.524. View